Genmab Confident It Has Edge Over Roche In Bispecific Battle

Epcoritamab Tipped To Lead Rival CD20xCD3 Drugs

 
• By Andrew McConaghie

Genmab may only recently have launched its first commercial operations with Tivdak, but is stepping up to co-market epcoritamab with AbbVie against the might of Roche in the new CD20xCD3 field.

Genmab Office Copenhagen - close up
Genmab only recently launched its commercial division with Tivdak, but is now preparing for a possible 2023 launch of epcoritamab. • Source: Genmab

More from Business

More from Scrip